Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

9473	Companies
185388	Keywords
117743	Articles
99274	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

PRESS RELEASE

published on 09/15/2025 at 16:45, 2 months 19 days ago

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Protagonist Therapeutics to present Phase 2b ANTHEM-UC study data on targeted oral peptide icotrokinra at UEGW Week 2025 in Berlin. Company focuses on advanced therapies in ulcerative colitis

Ulcerative Colitis Protagonist Therapeutics Icotrokinra Phase 2b ANTHEM-UC Study UEGW Week 2025
BRIEF

published on 09/11/2025 at 14:05, 2 months 23 days ago

Un acteur majeur sollicite l'approbation de l'EMA pour l'icotrokinra dans le traitement du psoriasis

Essais Cliniques Icotrokinra Psoriasis En Plaques Efficacité Du Traitement Demande D'admission À L'EMA
BRIEF

published on 09/11/2025 at 14:05, 2 months 23 days ago

Protagonist Seeks EMA Approval for Icotrokinra in Psoriasis

Clinical Trials Plaque Psoriasis Icotrokinra Treatment Efficacy EMA Application
PRESS RELEASE

published on 09/11/2025 at 14:00, 2 months 23 days ago

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Protagonist Therapeutics submits application to EMA for first approval of icotrokinra, an investigational targeted oral peptide blocking IL-23 receptor in plaque psoriasis treatment

Protagonist Therapeutics Plaque Psoriasis Treatment IL-23 Receptor Icoktrokinra EMA Submission
BRIEF

published on 08/26/2025 at 22:10, 3 months 9 days ago

Protagonist Therapeutics Engages in Key Investment Conferences

Clinical Trials Protagonist Therapeutics Investment Conferences Biopharmaceutical Development Icotrokinra And Rusfertide
BRIEF

published on 08/26/2025 at 22:10, 3 months 9 days ago

Protagonist Therapeutics participe à des conférences d'investissement clés

Essais Cliniques Thérapeutique Protagoniste Conférences D'investissement Développement Biopharmaceutique Icotrokinra Et Rusfertide
PRESS RELEASE

published on 08/26/2025 at 22:05, 3 months 9 days ago

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
Protagonist Therapeutics announced CEO's participation in investment bank conferences in September. Company's advanced Phase 3 clinical development and future plans highlighted

Protagonist Therapeutics Phase 3 Clinical Development NDA Submission Investment Bank Conferences Drug Discovery Programs
BRIEF

published on 08/25/2025 at 13:05, 3 months 10 days ago

Le Rusfertide de Protagonist Therapeutics reçoit la désignation de thérapie révolutionnaire de la FDA

Rusfertide Thérapeutique Protagoniste Polyglobulie Vraie Thérapie Révolutionnaire Phase 3 VÉRIFIER
BRIEF

published on 08/25/2025 at 13:05, 3 months 10 days ago

Protagonist Therapeutics' Rusfertide Receives FDA Breakthrough Therapy Designation

Protagonist Therapeutics Rusfertide Polycythemia Vera Breakthrough Therapy Phase 3 VERIFY
PRESS RELEASE

published on 08/25/2025 at 13:00, 3 months 10 days ago

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
Protagonist Therapeutics' rusfertide granted Breakthrough Therapy Designation by the FDA for polycythemia vera, complementing Orphan Drug and Fast Track designations. NDA filing on track for Q4

FDA Protagonist Therapeutics Rusfertide Breakthrough Therapy Designation NDA Filing

Accesswire

Published on 12/05/2025 at 02:35, 5 hours 59 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 6 hours 4 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 7 hours 34 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 9 hours 29 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 9 hours 34 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 08:05, 29 minutes ago

Smartmi Unveils the Air Purifier 3: Powerful, Smart, and Stylish Air Care for Modern Homes
Published on 12/05/2025 at 08:01, 33 minutes ago

Original-Research: Warimpex Finanz- und Beteiligungsholding AG (von East Value Research GmbH ):
Published on 12/05/2025 at 08:01, 33 minutes ago

Custodian Property Income REIT plc: Interim results for the period ended 30 September 2025
Published on 12/05/2025 at 08:00, 34 minutes ago

Swiss Prime Site Solutions Investment Fund Commercial (SPSS IFC) approaches the 500-million mark ahead of listing
Published on 12/05/2025 at 08:00, 34 minutes ago

Le Swiss Prime Site Solutions Investment Fund Commercial (SPSS IFC) croît et est sur le point de franchir la barre des 500 millions

Les Echos

Published on 12/04/2025 at 18:14, 14 hours 19 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 14 hours 34 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 14 hours 34 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 14 hours 49 minutes ago

Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 14 hours 49 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE